Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders
|
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders
09 February 2015 (101.49 Kb 29 sec) |
This page was last updated: 06 February 2015